Segment Data (Tables)

3 Months Ended

Dec. 25, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Business Segment

Selected information by business segment was as follows:

	Three Months Ended
	December 25, 2015			December 26, 2014
Net sales:
Specialty Brands	$	543.2		$	373.6
Specialty Generics	257.6			284.2
Nuclear Imaging	103.6			101.9
Net sales of operating segments	904.4			759.7
Other (1)	10.4			8.5
Net sales	$	914.8		$	768.2
Operating income:
Specialty Brands	$	272.0		$	148.2
Specialty Generics	118.2			140.5
Nuclear Imaging	15.0			4.8
Segment operating income	405.2			293.5
Unallocated amounts:
Corporate and allocated expenses (2)	(46.0		)	(39.8		)
Intangible asset amortization	(173.4		)	(124.8		)
Restructuring and related charges, net (3)	(6.4		)	(7.3		)
Operating income	$	179.4		$	121.6

(1) Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.

(2) Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.

(3) Includes restructuring-related accelerated depreciation.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's segments are as follows:

	Three Months Ended
	December 25, 2015		December 26, 2014
Acthar	$	286.7	$	266.4
Inomax	110.8		—
Ofirmev	66.9		71.4
Therakos immunotherapy	50.4		—
Other	28.4		35.8
Specialty Brands	543.2		373.6
Hydrocodone (API) and hydrocodone-containing tablets	36.7		34.0
Oxycodone (API) and oxycodone-containing tablets	28.9		47.0
Methylphenidate ER	31.2		48.6
Other controlled substances	109.7		111.9
Other	51.1		42.7
Specialty Generics	257.6		284.2
Nuclear Imaging	103.6		101.9
Other (1)	10.4		8.5
Net sales	$	914.8	$	768.2